Ombitasvir/paritaprevir/ritonavir+Dasabuvir

PreclinicalSmall molecule

Ombitasvir/paritaprevir/ritonavir+Dasabuvir is one of 6 small molecule programs targeting Esophageal Varices. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal VaricesActive, not recruiting

Esophageal VaricesPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Esophageal Varices

#DrugCompanyPhaseTrials

Coreg

Akero Therapeutics

Approved

6 2

Inderal

WWyeth-Lederle Vaccines

Approved

4 3

Sandostatin

Sun Pharma

Approved

2 4

Anticoagulation Agents

IInari Medical

Preclinical

1 5

Ledipasvir/sofosbuvir

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Preclinical

1 6

Ombitasvir/paritaprevir/ritonavir+Dasabuvir

PParc de Salut Mar

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Esophageal Varices1 trial

Impact of Antiviral Therapy on Gastroesophageal Varices.

Completed·PParc de Salut Mar··NCT02758509·237 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ombitasvir/paritaprevir/ritonavir+Dasabuvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ombitasvir/paritaprevir/ritonavir+Dasabuvir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ombitasvir/paritaprevir/ritonavir+Dasabuvir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Parc de Salut Mar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PParc de Salut Mar

Ombitasvir/paritaprevir/ritonavir+Dasabuvir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Esophageal Varices1 trial

References

Drug Info

Quick Facts

Related News